Conversion From Mycophenolate Mofetil to Mycophenolate Sodium in Renal Transplant

Novartis

Status and phase

Completed

Phase 4

Conditions

Kidney Transplantation

Treatments

Drug: Mycophenolate sodium

Study type

Interventional

Funder types

Industry

Identifiers

NCT00646737

CERL080ABR02

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and the tolerability of the substitution of mycophenolate mofetil for enteric-coated mycophenolate sodium in a population of stable renal transplant patients in Brazil, in a treatment regimen of immunosuppressants with tacrolimus and mycophenolate mofetil.

Enrollment

18 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

Age between 18 and 65 years;
First or second renal transplant within at least 12 weeks;
Clinical stability, in the opinion of the investigator, during at least 8 weeks before inclusion in the study;
Women of reproductive age must use contraceptive methods and present negative results in pregnancy test Serum creatinine < 2.5 mg/dE; Patients in use of a immunosuppression regimen based on tacrolimus and mycophenolate mofetil (generic or not, in any dose), who present gastrointestinal symptoms Capacity to complete the study requirements;

Exclusion criteria History of acute rejection,

Proven or not by biopsy, in the last 2 months before the study;
Recipients of multiple organs;
Participation in any clinical investigation in the last 6 months before the present study;
Thrombocytopenia (platelets <75,00O/mm3), leucopenia (total leukocytes <4,000/mm3)and/or anemia (hemoglobin <9.0 gldL) before inclusion in the study;
Clinically important disease, in the opinion of the investigator, including systemic infection, within 2 weeks before inclusion in the study;
Presence of any neoplasia, current or past, except resected basal cell carcinoma;
Any surgical or medical condition that could significantly alter the absorption, distribution, metabolism or excretion of medicines or that could put the patient in danger as a result of participation in the study;
History of drug or alcohol abuse within previous 12 months of inclusion in the study, Current or prior use in the last 2 months of bile acid-adsorbing resins(cholestyramine and colestipol).